USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Ustav Organicke Chemie A Biochemie AV CR, V.v.i.

USPTO PatentsView assignee record - 26 granted patents across 26 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

26
Total patents granted
26
CPC technology areas
11.5
Avg claims per patent
+86%
5-year grant velocity

The verdict

According to USPTO PatentsView, Ustav ranks #11,855 of 50,000 tracked US assignees by granted-patent volume, with 26 patents across 26 technology areas.

#11,855
of 50,000 US assignees by volume
Top 38%
by Innovation Score (39.6/100)
11.5
avg claims per patent
+86%
grant velocity, last 5 yrs

Portfolio overview

Ustav Organicke Chemie A Biochemie AV CR, V.v.i. has been granted 26 US utility patents between 2016 and 2025, placing Ustav Organicke Chemie A Biochemie AV CR, V.v.i. at #11,855 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 26 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Ustav Organicke Chemie A Biochemie AV CR, V.v.i. is one of the more focused assignees in the PatentsView dataset. By volume, Ustav sits between Trutag Technologies, Inc. (26 patents, rank #11,849) and Vanchip (tianjin) Technology Co., Ltd. (26 patents, rank #11,857) - the closest US assignees by grant volume. The composite Innovation Score of 39.6/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 13 grants, compared with 7 in the 2015–2019 window, a +86% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Ustav Organicke Chemie A Biochemie AV CR, V.v.i.'s 11.5 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 26 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Ustav's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Ustav holds 26 patents at rank #11,853, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Ustav

By rank, the assignees closest to #11,853 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Ustav's primary technology class.

Ustav's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 38% higher than 62% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 201620182019202020212022202320242025 6
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Ustav Organicke Chemie A Biochemie AV CR, V.v.i. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 1 3.8%
2018 4 15.4%
2019 2 7.7%
2020 4 15.4%
2021 4 15.4%
2022 3 11.5%
2023 1 3.8%
2024 1 3.8%
2025partial year 6 23.1%

Grant record at a glance

Portfolio Volume 26 grants
CPC subclasses 26
Avg. claims / grant 11.5
Velocity +86%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#11,855

of 50,000 tracked assignees

Innovation Score

39.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Ustav Organicke Chemie A Biochemie AV CR, V.v.i. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Ustav Organicke Chemie A Biochemie AV CR, V.v.i. ranks #11,855 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Ustav Organicke Chemie A Biochemie AV CR, V.v.i. hold?
Ustav Organicke Chemie A Biochemie AV CR, V.v.i. holds 26 US utility patents granted between 2016 and 2025, spanning 26 technology areas.
What is Ustav Organicke Chemie A Biochemie AV CR, V.v.i.'s Innovation Score?
Ustav Organicke Chemie A Biochemie AV CR, V.v.i. has an Innovation Score of 39.6 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Ustav Organicke Chemie A Biochemie AV CR, V.v.i. focus on?
Ustav Organicke Chemie A Biochemie AV CR, V.v.i.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 14 patents. Grants appear in 26 CPC subclasses total.
Is Ustav Organicke Chemie A Biochemie AV CR, V.v.i.'s patent grant rate increasing or decreasing?
Ustav Organicke Chemie A Biochemie AV CR, V.v.i.'s recent grant velocity is +86% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.
What does claim depth mean for Ustav Organicke Chemie A Biochemie AV CR, V.v.i.'s patents?
Ustav Organicke Chemie A Biochemie AV CR, V.v.i.'s patents average 11.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Ustav Organicke Chemie A Biochemie AV CR, V.v.i. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Ustav's 26 grants land it in the top 38% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Ustav ranks #11,855 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.